FAIRFIELD, Conn., Sept. 20 /PRNewswire-FirstCall/ -- Competitive
Technologies, Inc. (Amex: CTT) announced today that it has granted an
exclusive option to research the manufacture and use of CTT's nanotechnology
bone biomaterial for dental applications to a major, diverse dental products
company. CTT has an exclusive agreement with the University of South Carolina
Research Foundation (USCRF) to license and commercialize this nanotechnology.
The technology, an injectible calcium phosphate-based biomaterial, is from the
work of Dr. Brian Genge, a research professor in the Department of Chemistry
and Biochemistry at the University of South Carolina.
"The agreement to develop products using USCRF's innovative nanoparticle
biomaterial technology in the dental products market is an example of CTT
fulfilling unsatisfied market needs from its portfolio of technology
solutions," said Suzanne N. B. Alent, CTT's VP Marketing and Business
Development. "This agreement establishes CTT as a value-added partner in the
dental medical device industry."
Applications in this agreement are for dental use. The technology can also
be applied to human bones, especially related to the spine, and veterinary
uses. The bone biomaterial technology is an easily flowable, moldable paste
that conforms to and interdigitates with the host bone. It rapidly hardens
itself in vivo, forming a solid bone-like structure capable of stabilizing
fractured bone within 15 minutes. The technology has superior compressive
strength making it suitable for weight and non-weight bearing bones, and is
both machinable and drillable.
John B. Nano, CTT's President and CEO said, "Bone biomaterial is just one
of the important innovative technologies in our exciting portfolio. CTT is
actively marketing and commercializing several technologies, including
homocysteine assays, sexual dysfunction treatment, video compression and
decoding technology, sunless tanning application, silicon carbide wafer
testing, animated graphical password security technology, language-mastering
software, specialty chemical compounds, pollution abatement process, and the
Therapik(R) thermal therapy."
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, is a full service
technology transfer and licensing provider focused on the technology needs of
its customers and transforming those requirements into commercially viable
solutions. CTT is a global leader in identifying, developing and
commercializing innovative technologies in life, digital, nano, and physical
sciences developed by universities, companies and inventors. The global market
for technology transfer services is estimated at $150 billion annually. CTT
maximizes the value of intellectual assets for the benefit of its customers,
clients and shareholders. Visit CTT's website: http://www.competitivetech.net
Statements about our future expectations, including development and
regulatory plans, and all other statements in this document other than
historical facts are "forward-looking statements" within the meaning of
applicable Federal Securities Laws, and are not guarantees of future
performance. These statements involve risks and uncertainties inherent in our
business, including those set forth under the caption "Risk Factors" in our
Prospectus filed with the SEC on May 6, 2004 under Rule 424 (b)(3) of the
Securities Act of 1933, and other factors that may be described in our other
filings with the SEC, and are subject to change at any time. Our actual
results could differ materially from these forward-looking statements. We
undertake no obligation to update publicly any forward-looking statement.
Direct inquiries to:
Johnnie D. Johnson, Strategic IR, Inc. E-mail: email@example.com
Tel. (212) 754-6565; Fax (212) 754-4333 E-mail: firstname.lastname@example.org
SOURCE Competitive Technologies, Inc.